Dulaglutide

In human trials

• 1.5 mg

  under the skin · weekly · for 4 weeks

  Effects of Glucagon-Like Peptide-1 Analogs on SexualityPHASE2 · NCT04687514

  “Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c..”

• See source wording

  under the skin · for 4 weeks

  Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 DiabetesNot stated · NCT04374578

  “Dulaglutide 1.5 MG/ML.”

• See source wording

  under the skin · weekly

  GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntolerancePHASE2 · NCT04731272

  “Dulaglutide 0.75Mg/0.5Ml Inj Pen.”

• See source wording

  under the skin · every 4 weeks

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesPHASE3 · NCT04255433

  “Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered as subcutaneous (SC) injection once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or MTD tolerated by the participant (5 mg QW or 10 mg QW) for up to 5 years..”

• See source wording

  under the skin · for 26 weeks

  A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 DiabetesPHASE3 · NCT02963766

  “Participants received placebo administered subcutaneously (SC) for 26 weeks during the double-blind period and open-label 0.75 mg/week dulaglutide for 26 weeks during the Open Label Extension (OLE)..”

• See source wording

  under the skin · once daily · for 26 weeks

  A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 DiabetesPHASE3 · NCT01624259

  “1.5 mg LY2189265.”

• See source wording

  under the skin · weekly · for 4 weeks

  A Study of LY3493269 in Participants With Type 2 DiabetesPHASE1 · NCT04515576

  “Participants received 1.5 mg dulaglutide subcutaneously (SC) once weekly (QW) for 4 weeks..”

• See source wording

  under the skin · daily

  Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)Not stated · NCT05946148

  “Empagliflozin 10mg daily, as add-on to previous treatment regimen..”

• See source wording

  under the skin · every 2 weeks · for 4 weeks

  Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusPHASE2 · NCT07677891

  “PG-102(MG12) 60mg.”

• See source wording

  under the skin · once a week

  A Study of HS-20094 in Patients With T2DMPHASE2 · NCT06901648

  “HS-20094 5mg.”

• See source wording

  under the skin · once daily

  A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes MellitusPHASE3 · NCT01648582

  “1.5 mg Dulaglutide.”

• 1.5 mg

  under the skin · once a week

  A Study of IBI362 in Chinese Patients With Type 2 DiabetesPHASE2 · NCT04965506

  “Participants receive Dulaglutide 1.5mg by subcutaneous (SC) injection once a week..”

• See source wording

  under the skin · every 4 weeks · for 40 weeks

  A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)PHASE4 · NCT05564039

  “The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5mg to 15 mg) until 15 mg or MTD was reached..”

• See source wording

  under the skin · weekly

  A Study of TG103 Injection in Type 2 Diabetes SubjectsPHASE2 · NCT05348122

  “TG103, 15 mg,Q2W.”

• See source wording

  under the skin · once a week · for 52 weeks

  A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminPHASE3 · NCT06257966

  “Exendin-4 Fc fusion protein injection(1.2mg）.”

• See source wording

  under the skin · daily

  A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes MellitusPHASE3 · NCT01644500

  “1.5 mg Dulaglutide.”

• 0.75 mg

  single injection

  Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery PatientsPHASE4 · NCT03743025

  “Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery.”

• 1.5 mg

  for 12 weeks

  Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney DiseasePHASE2 · NCT05254418

  “All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication.”

• See source wording

  under the skin · every 2 weeks

  Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminPHASE3 · NCT03684642

  “Efpeglenatide 4 mg.”

• See source wording

  under the skin · once a week

  A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusPHASE3 · NCT06235086

  “TG103 injection, 7.5mg, 15 mg, SC, once a week.”

• See source wording

  under the skin · weekly · for 4 weeks

  A Study of Dulaglutide in Chinese ParticipantsPHASE1 · NCT01667900

  “0.5 mg Dulaglutide (Part A-Healthy).”

• See source wording

  under the skin · weekly · for 52 weeks

  A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 DiabetesPHASE3 · NCT03861052

  “5 mg Tirzepatide.”

• See source wording

  weekly · for 4 weeks

  Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseNA · NCT03590626

  “0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks.”

• 1.5 mg

  weekly · for 12 weeks

  Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) AnaloguesPHASE2 · NCT03204396

  “Application of Dulaglutide (Trulicity®) 1.5 mg s.c.”

• See source wording

  weekly

  GLP-1 REceptor Agonists and Real World EvIdeNceNot stated · NCT03959865

  “Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg.”

• 1.5 MG

  under the skin

  A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminPHASE2 · NCT07109700

  “Dulaglutide 1.5 MG.”

• 0.75 mg

  under the skin · weekly · for 36 weeks

  A Study of Dulaglutide in Japanese Participants With Type 2 DiabetesPHASE4 · NCT02750410

  “After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.”

• 0.75 mg

  under the skin · single dose

  A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese SubjectsPHASE1 · NCT05459285

  “Subjects receive 14028 injection in the study, 0.75mg, once.”

• 1.5 mg

  under the skin · weekly · for 24 weeks

  Dulaglutide and Insulin MicrosecretiON in Type 1 DiabetesPHASE2 · NCT03668470

  “Dulaglutide 1.5mg : One injection per week during 24 weeks.”

• See source wording

  by mouth · daily

  Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 DiabetesPHASE3 · NCT03015220

  “Oral semaglutide 3 mg.”

• See source wording

  by mouth · once daily

  A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy ParticipantsPHASE1 · NCT01436201

  “Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17.”

• See source wording

  under the skin · three times a day · for 16 weeks

  The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.PHASE4 · NCT05005741

  “Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation..”

• 1.5 mg

  under the skin · weekly · for 52 weeks

  Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)PHASE4 · NCT03648554

  “dulaglutide (TRULICITY®) 1.5 mg.”

• See source wording

  under the skin · weekly

  A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 DiabetesPHASE3 · NCT04809220

  “Participants received 1.5 mg of dulaglutide given weekly subcutaneously (SC) during the 52-week treatment period.”

• See source wording

  under the skin · weekly

  A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)PHASE3 · NCT01621178

  “0.75 mg Dulaglutide.”